American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.
The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.
Mason
Vicki L
VL
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. vicki.mason@thomsonreuters.com
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational